M&A Deal Summary

Meridian Bioscience Acquires Euprotein

On May 2, 2022, Meridian Bioscience acquired life science company Euprotein

Acquisition Highlights
  • This is Meridian Bioscience’s 5th transaction in the Life Science sector.
  • This is Meridian Bioscience’s 8th transaction in the United States.
  • This is Meridian Bioscience’s 2nd transaction in New Jersey.

M&A Deal Summary

Date 2022-05-02
Target Euprotein
Sector Life Science
Buyer(s) Meridian Bioscience
Deal Type Add-on Acquisition

Target

Euprotein

North Brunswick, New Jersey, United States
Euprotein offers custom development and production of bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. Euprotein is based in North Brunswick, New Jersey.

Search 215,074 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Meridian Bioscience

Cincinnati, Ohio, United States

Category Company
Founded 1976
Sector Life Science
Employees702
Revenue 318M USD (2021)
DESCRIPTION

Meridian is a life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Meridian was founded in 1976 and is based in Cincinnati, Ohio.


DEAL STATS #
Overall 11 of 11
Sector: Life Science M&A 5 of 5
Type: Add-on Acquisition M&A Deals 7 of 7
State: New Jersey M&A 2 of 2
Country: United States M&A 8 of 8
Year: 2022 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-23 Otsuka America Pharmaceutical - North American BreathTek business

Princeton, New Jersey, United States

Otsuka America Pharmaceutical's North American BreathTek business is a urea breath test for the detection of Helicobacter pylori. Otsuka America Pharmaceutical's North American BreathTek business is based in Princeton, New Jersey.

Buy $20M